ADVANCES IN THE TREATMENT OF METASTATIC GASTRIC CANCER
FACULTY
David Herman Ilson, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY
Caroline Kuhlman, MS, APRN-BC, AOCNP
Tucker Gosnell Center for Gastrointestinal Cancers
Massachusetts General Hospital
Boston, MA
Read frequently asked questions submitted by your peers.
Electronic newsletter now available:
Treatment Strategies for Metastatic Gastric Cancer:
Selecting Chemotherapy Regimens and Managing Toxicities
PURPOSE STATEMENT
Advances in the Treatment of Metastatic Gastric Cancer will examine current and emerging therapies for gastric cancer, potential adverse effects associated with treatment regimens, and their potential impact on patient survival and quality of life.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
- Describe the increasing incidence of certain types of gastric cancers.
- Identify the treatment-limiting toxicities of chemotherapy for metastatic gastric cancer.
- Recognize the role of supportive care in managing chemotherapy-induced toxicities.
- Discuss newer chemotherapeutic approaches to the treatment of metastatic gastric cancer.
TARGET AUDIENCE
Advances in the Treatment of Metastatic Gastric Cancer is intended for medical, surgical, and radiation oncologists and oncology nurses, as well as other healthcare professionals interested in the management of patients with gastric cancer.
ACCREDITATION INFORMATION
Expiration date: May 22, 2008
Physicians: Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Med-IQ designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses (CBRN): Med-IQ is a provider approved by the California Board of Registered Nursing, Provider Number CEP #14745, for 1.0 Contact Hours.
Pharmacists:
1 contact hour (0.100 CEU) of credit for pharmacists. This activity is co-sponsored by Medical Education Collaborative, Inc. (MEC) and Med-IQ. MEC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Enduring ACPE # 815-999-07-034-H01. The program is designed for all pharmacists.
Other Credit Information
Nurse Practitioners: Med-IQ is accredited by ACCME to provide continuing medical education for physicians, and will provide nurse practitioners who successfully complete the activity with a Statement of Participation indicating that the activity was designated for 1 AMA PRA Category 1 CreditTM.
Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 CreditTM for the PRA from organizations accredited by ACCME.
Disclosure Policy
It is the policy of Med-IQ that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during presentation(s). Individuals who refuse to disclose will be disqualified from all aspects associated with this CME activity. Med-IQ has policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
David Ilson
Consulting fees/advisory boards: sanofi-aventis U.S.
Fees received for promotional/non-CME activities: Merck & Co., Inc.
Contracted research: Genentech, Bristol-Myers Squibb, sanofi-aventis U.S.
Carol Kuhlman
Consulting fees/advisory boards: sanofi-aventis U.S.
Fees received for promotional/non-CME activities: Merck & Co., Inc.
Med-IQ Disclosure
Reshma Carter has disclosed that her spouse is an employee of Novartis Pharmaceuticals.
All other employees of Med-IQ have no financial relationships to disclose.
MEC Disclosure
The employees of Medical Education Collaborative have no financial relationships to disclose.
Acknowledgement of Commercial Support
This educational series is supported by an educational grant from sanofi-aventis U.S.